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Abstract
Introduction: Sepsis is responsible for important alterations in the pharmacokinetics of antibiotics. Continuous
renal replacement therapy (CRRT), which is commonly used in septic patients, may further contribute to
pharmacokinetic changes. Current recommendations for antibiotic doses during CRRT combine data obtained from
heterogeneous patient populations in which different CRRT devices and techniques have been used. We studied
whether these recommendations met optimal pharmacokinetic criteria for broad-spectrum antibiotic levels in
septic shock patients undergoing CRRT.
Methods: This open, prospective study enrolled consecutive patients treated with CRRT and receiving either
meropenem (MEM), piperacillin-tazobactam (TZP), cefepime (FEP) or ceftazidime (CAZ). Serum concentrations of
these antibiotics were determined by high-performance liquid chromatography from samples taken before (t =0 )
and 1, 2, 5, and 6 or 12 hours (depending on the b-lactam regimen) after the administration of each antibiotic.
Series of measurements were separated into those taken during the early phase (< 48 hours from the first dose) of
therapy and those taken later (> 48 hours).
Results: A total of 69 series of serum samples were obtained in 53 patients (MEM, n = 17; TZP, n = 16; FEP, n =8 ;
CAZ, n = 12). Serum concentrations remained above four times the minimal inhibitory concentration for
Pseudomonas spp. for the recommended time in 81% of patients treated with MEM, in 71% with TZP, in 53% with
CAZ and in 0% with FEP. Accumulation after 48 hours of treatment was significant only for MEM.
Conclusions: In septic patients receiving CRRT, recommended doses of b-lactams for Pseudomonas aeruginosa are
adequate for MEM but not for TZP, FEP and CAZ; for these latter drugs, higher doses and/or extended infusions
should be used to optimise serum concentrations.
Introduction
Severe sepsis and septic shock are major causes of morbid-
ity and mortality in ICUs [1-3]. Antibiotic treatment, if
adequate and given early [4,5], remains of paramount
importance to optimise chances of survival [6]. Several
studies have shown the crucial impact of the first 24 hours
of antimicrobial treatment on outcome [7]. In addition to
timing, the chosen antibiotic should target the potential
pathogens involved, taking local susceptibility patterns
into account. To be effective, the doses given should reach
therapeutic concentrations in the blood and at the site of
infection [8-10]. Sepsis can significantly alter the pharma-
cokinetics of antimicrobials and result in subtherapeutic
drug concentrations [11,12], potentially contributing to
decreased bacterial killing, therapeutic failure and emer-
gence of resistance.
Acute renal failure is a common complication of sepsis.
In septic patients, continuous renal replacement therapy
(CRRT) is often preferred to conventional haemodialysis
because it is better tolerated haemodynamically. However,
CRRT can further alter the pharmacokinetics of antibiotics
[13]. These changes depend on several variables, such as
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tions and the type of membrane used - each of these vari-
ables introducing additional variability in expected drug
concentrations [14]. A recent systematic review addressed
the importance of all these factors for antibiotic prescrip-
tion [15], but the most recent recommendations on anti-
biotic dosing during CRRT [16] were established using
evidence from studies that included a limited number of
patients, with varying inclusion/exclusion criteria and
receiving different types of CRRT [17-20]. Serum measure-
ments were usually performed at steady state, which also
limits the extrapolation of results to the early phase of sep-
sis, during which patients are often haemodynamically
unstable. Finally, these recommendations have never been
validated in a septic ICU population suffering from multi-
ple organ failure.
The objective of our study was to evaluate whether
the recommended doses of broad-spectrum b-lactams
[16] result in appropriate serum concentrations in ICU
patients with severe sepsis and septic shock receiving
CRRT.
Materials and methods
Study design, patients and inclusion criteria
This observational, prospective study was conducted
between January 2008 and May 2009, in a 35-bed medico-
surgical ICU at Erasme Hospital, Brussels (Belgium). The
study was approved by the local ethics committee (Comité
d’Ethique Hospitalo-Facultaire Erasme-ULB, reference
number OM021) and informed consent was obtained
from patients or their closest relative. The study was con-
ducted in compliance with the Helsinki Declaration for
human research.
Inclusion criteria were as follows: age > 18 years; diagno-
sis of severe sepsis or septic shock according to standard
criteria [1]; acute renal failure treated with CRRT; and
receiving at least one of meropenem (MEM), piperacillin-
tazobactam (TZP), cefepime (FEP) or ceftazidime (CAZ).
All patients fulfilling these criteria were included consecu-
tively. Exclusion criteria were pregnancy, burns and cystic
fibrosis. Patients receiving different study drugs succes-
sively were included more than once.
Antibiotic treatment and serum samples
The choice of antibiotic was at the discretion of the clini-
cians and was based on local guidelines. All included
patients received a first dose (loading dose) of 1 g MEM,
4.0/0.5 g TZP, or 2 g FEP or CAZ. The highest daily dose
was taken from published recommendations [16] for
patients on CRRT, whether on continuous venovenous
haemofiltration (CVVH) or continuous venovenous hae-
modiafiltration (CVVHDF): 1 g twice daily for MEM and
2 g twice daily for FEP and CAZ, whereas for TZP the
daily dose was adapted to the European format (that is,
4.0/0.5 g four times daily). Each antibiotic dose was admi-
nistered as a 30-minute infusion.
Blood samples for drug assays (3 to 4 ml blood) were
drawn from the arterial line on the day of inclusion, and
then every second day during CRRT treatment when pos-
sible. On each sampling day, a series of blood samples was
drawn to obtain a pharmacokinetics curve for each dose:
immediately before the antibiotic administration (0 hours),
and then 1, 2, 5, and 6 or 12 hours (depending on the anti-
biotic regimen) after the start of the infusion. The exact
sampling times were recorded. Blood was collected in
plain tubes and centrifuged at 3,000 rpm at 4°C for 10
minutes; the supernatant was separated immediately and
kept at -80°C until analyses were performed. Sample series
were grouped according to the day of sampling relative to
the start of the antibiotic treatment; that is, into the early
phase (< 48 hours from the first dose) or the late phase
(> 48 hours).
Continuous renal replacement therapy
CRRT was performed through a double-lumen catheter
inserted into a large vein. CVVH or CVVHDF was per-
formed using a Prisma or PrismaFlex machine (Hospal,
Meyzieu, France), with an AN69 haemofilter (Gambro
Lundia AB, Lund, Sweden). Characteristics of the CRRT
were recorded for each patient at each blood sampling
time.
Serum antibiotic analyses
Serum concentrations of all antibiotics were measured in
the clinical chemistry department by high-performance
liquid chromatography connected to UV spectrophoto-
metry. Briefly, 1 ml methanol was added to 500 μls e r u m
in order to precipitate proteins. The supernatant was
separated and evaporated, and the residue was solubilised
in 50 mmol/l phosphate buffer, pH 3.8. A 30 μl sample
was injected into an Agilent 1200 series chromatograph
(Agilent, Diegem, Belgium) equipped with a YMC ODS
AQ column (YMC GmbH, Dinslaken, Germany). Anti-
biotics were separated within 60 minutes in an acetoni-
trile-phosphate buffer gradient. UV absorbance was
monitored at 204 nm for tazobactam and MEM, and at
240 nm for piperacillin, FEP and CAZ. Cefoperazone was
used as the internal standard. The limit of quantification
was 0.2 μg/ml for tazobactam and 2.0 μg/ml for the other
antibiotics. Between-day imprecision was less than 6.5%.
As the pharmacokinetics of piperacillin and tazobactam
are highly correlated [21] and tazobactam serum concen-
tration curves followed those of piperacillin in our study,
only the latter were used in the analysis.
The validation of the analytical method was performed
daily, according to the published acceptance criteria for
specificity, linearity, accuracy, precision (intra-day
(repeatability), inter-day (intermediate precision)) and
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chromatographic conditions, MEM, TZP, FEP and CAZ
were identified by sharp and well-resolved peaks. The
stability of plasma samples is at least 1 month at -80°C.
Pharmacokinetic analysis
To determine mean concentrations, each series of time
points from each patient was linearised using a logarith-
mic transformation. Each curve was then reconstructed
using fixed time points and the mean concentrations
were calculated. The peak concentration was the con-
centration measured 1 hour after the start of the
3 0 - m i n u t ea n t i b i o t i ci n f u s i o n .T h ea r e au n d e rt h ec u r v e
(AUC) for a given drug was calculated from the mean
AUCs for each series for a given drug, using the raw
concentrations. The AUC was calculated using the tra-
pezoidal rule. Also, AUCs were used to estimate differ-
ences in drug exposure between measurements made <
48 hours and > 48 hours from the onset of antibiotic
therapy.
The volume of distribution (Vd)f o rag i v e nd r u gw a s
the mean of all Vd values from the series taken under
that drug, using the following formula applied to the
linearised series:
Vd = dose/C0
where C0 is the concentration at the start of the infu-
sion, and:
lnC = −ke.t +l n C0
where C is the concentration at time t,a n dke is the
slope. The total clearance (CL) and the elimination half-
life (t1/2) were calculated with the formulae:
ke =C L / Vd and t1/2 = 0.693/ke
No pharmacokinetic/pharmacodynamic profile was
measured for loading doses.
Pharmacodynamic analysis
In the pharmacodynamic analyses, we considered the
minimal inhibitory concentrations (MICs) defined by
the European Committee on Antimicrobial Susceptibility
Testing as the clinical breakpoints for the pathogens
most frequently encountered in nosocomial or ICU
infections [23]. As Pseudomonas aeruginosa is the most
frequent, serious pathogen in the ICU and causes infec-
tion associated with the highest mortality rates [24], we
used the clinical breakpoint of this pathogen as the tar-
get MIC. Sensitivity MIC thresholds for this pathogen
are: ≤ 2 μg/ml for MEM, ≤ 16 μg/ml for TZP, and ≤ 8
μg/ml for CAZ and FEP.
Some clinical data suggest that maximal killing of bac-
teria by b-lactams occurs when serum concentrations
are maintained above the MIC of the causative patho-
gens for extended periods [25-28]. Achievement of max-
imal bactericidal effect requires 40%, 50% and 60 to 70%
coverage of the dose interval for carbapenems, penicil-
lins and cephalosporines, respectively [29]. To achieve
optimal bactericidal activity, the adequacy of b-lactam
therapy in our study was assessed by measuring the
time that the concentration was above more than four
times the target MIC. This optimal time that the con-
centration was above more than four times the target
MIC for each drug was considered to be ≥ 40% of the
time interval between two doses for MEM, ≥ 50% for
TZP, or ≥ 70% for FEP and CAZ [29]. We classified
each patient as having an adequate or inadequate phar-
macokinetic/pharmacodynamic profile according to the
percentage of time during which serum drug concentra-
tions remained above four times the clinical breakpoint
for P. aeruginosa;t h a ti s ,≥ 8 μg/ml for MEM, ≥ 64 μg/
ml for TZP, and ≥ 32 μg/ml for FEP and CAZ. Finally,
using the concentrations obtained in our population, we
calculated the probability of achieving targets for the
time that the concentration was above more than four
times the target MIC for other MICs found in ICU-iso-
lated Gram-negative bacteria.
Statistical analysis
Descriptive statistics were performed for all study vari-
ables. Discrete variables were expressed as counts (percen-
tage), and continuous variables as means ± standard
deviation or median (25th to 75th percentiles). Differences
between groups (early versus late) were assessed using
Student’s t test. P < 0.05 was considered statistically
significant.
Results
Patients and series of samples
We included 53 patients, whose demographic and clini-
cal characteristics are presented in Table 1. MEM was
g i v e ni n1 7p a t i e n t s ,T Z Pi n1 6p a t i e n t s ,F E Pi ne i g h t
patients and CAZ in 12 patients. Sixty-nine series of
samples were obtained: MEM, n =2 2 ;T Z P ,n = 21;
FEP, n = 11; CAZ, n = 15.
Nineteen patients were treated with CVVHD and 34
with CVVHDF. The mean blood flow rate was 150 ±
24 ml/minute. The mean ultrafiltration rate was 22 ±
12 ml/kg/hour. Twenty-two of the 53 patients underwent
fluid removal; in those patients, the removal rate was
158 ± 140 ml/hour. The mean dialysate rate was 23 ±
9 ml/kg/hour.
Pharmacokinetic data and pharmacodynamic analysis
Pharmacokinetic data are shown in Table 2. There was a
marked inter-individual variation in all pharmacokinetic
parameters; Vd w a si n c r e a s e df o ra l lf o u rd r u g sw h e n
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lower peak concentration. There was no significant
impact of the technique (CVVHD versus CVVHDF) on
the pharmacokinetics of the studied drugs (data not
shown).
Figures 1, 2, 3 and 4 show the concentrations of MEM,
TZP, FEP and CAZ over time, separated into early (< 48
hours) and later (> 48 hours) phases of treatment. MEM
concentrations were significantly higher in the late phase
(> 48 hours) than in the early phase (< 48 hours) (Stu-
dent’s t test, P = 0.018). Although serum concentrations of
TZP, FEP and CAZ were higher after 48 hours of treat-
ment, there was no statistically significant difference
between early and later concentrations of these antibiotics.
Pharmacodynamic analyses for each antibiotic against
P. aeruginosa clinical breakpoints are summarised in
Table 3. The pharmacokinetic/pharmacodynamic target
was reached in 81% of patients treated with MEM, 71%
with TZP and 53% with CAZ but in none of the
patients receiving FEP.
We calculated the probability of attaining the target
time that the drug concentration was above more than
four times the target MIC for several MIC values
(Table 4). The concentrations would reach this target in
> 90% of cases with pathogens for MEM with MICs of
one or less, for TZP with MICs of eight or less, and for
FEP and CAZ with MICs of two or less.
Discussion
In this population of patients with severe sepsis and
septic shock treated with CRRT, we showed that the
recommended doses for broad-spectrum b-lactams are
generally insufficient to maintain therapeutic serum con-
centrations greater than four times the MIC of P. aerugi-
nosa. In the first 48 hours of treatment, 29%, 34%, 100%
and 62% of our patients treated with MEM, TZP, FEP
and CAZ, respectively, never reached the pharmacoki-
netic target. After 48 hours of treatment, the drug con-
centrations obtained were higher (significantly different
only for MEM), but they remained insufficient in many
patients. Despite the prolonged t1/2, we did not find sig-
nificant drug accumulation for TZP, FEP and CAZ over
time. This finding could be due to several concomitant
factors that may affect drug concentrations, such as
changes in CRRT settings, modification in filter efficacy,
renal recovery with additional drug clearance, fluids and
vasoactive agent administration with related changes in
drug Vd [15]. Also, the smaller number of patients evalu-
ated for these three drugs could have limited this analy-
sis, and therefore larger studies are warranted to address
this question. If we apply our results to other MICs, the
observed concentrations for all antibiotics were adequate
in 90% of patients only for MICs lower than the clinical
breakpoint of Pseudomonas spp., which correspond to
MICs of sensitive Enterobacteriacea.
Reaching high target concentrations early in the
course of treatment seems particularly important in
severely ill patients [30], especially given the heteroge-
neous nature of these patients [31]. In such patients, the
pharmacokinetics is altered both in terms of distribution
(sepsis itself can modify the Vd, resuscitation measures
and nutritional factors) and of elimination (drains,
altered metabolism and clearance changes). The higher
Table 1 Patient demographic and haemodynamic data
Patients (n)5 3
Mean age (years) 62 ± 16
Male/female 30/23
Body mass index 26 ± 8
Medical/surgical admission 31/22
Septic shock 12
ICU stay before inclusion (days) 4 (0 to 33)
Mechanical ventilation 37 (70%)
Co-morbidities
Chronic obstructive pulmonary disease 10 (19%)
Diabetes mellitus 15 (28%)
Heart disease 19 (36%)
Liver cirrhosis 9 (17%)
Solid organ transplantation 8 (15%)
Malignancy 8 (15%)
Data are expressed as number (percentage), median (range) or mean ±
standard deviation.
Table 2 Pharmacokinetic parameters of the four antibiotics
Antibiotic
(number of series)
Vd (l/kg) Cmax (μg/ml) Cmin (μg/ml) AUC (mg/hour/ml) CL (ml/minute/kg) t1/2 (hours)
MEM 1 g twice daily (n = 22) 0.45
(0.20 to 3.03)
26
(15 to 67)
6
(2 to 11)
134
(61 to 291)
1.15
(0.54 to 3.37)
4.39
(2.61 to 30.5)
TZP 4.0/0.5 g four times daily (n = 21) 0.44
(0.22 to 1.72)
138
(36 to 262)
60
(4 to 155)
527
(62 to 1378)
1.15
(0.27 to 6.26)
4.16
(1.05 to 15.3)
FEP 2 g twice daily (n = 11) 0.55
(0.33 to 0.94)
43
(28 to 83)
11
(3 to 22)
379
(148 to 483)
1.04
(0.43 to 2.97)
6.17
(3.30 to 22.9)
CAZ 2 g twice daily (n = 15) 0.37
(0.22 to 0.84)
78
(54 to 118)
24
(5 to 46)
536
(258 to 906)
0.52
(0.13 to 1.61)
7.74
(2.52 to 33.5)
Data shown as median (minimum to maximum). Vd, volume of distribution; Cmax, peak concentration; Cmin, trough concentration; AUC, area under the curve; CL,
total clearance; t1/2, elimination half-life; MEM, meropenem; TZP, piperacillin-tazobactam; FEP, cefepime; CAZ, ceftazidime.
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described in studies on aminoglycosides [32,33] and
vancomycin [34]. We recently demonstrated an
increased Vd and a high variability of serum antibiotic
concentrations in ICU patients with severe sepsis and
septic shock [14].
Effective cure of infection in ICU patients can be com-
promised for other reasons. First, ICU patients are fre-
quently immunosuppressed because of underlying
diseases, treatments, or other medical interventions [28].
Impairments in neutrophil and monocyte/macrophage
functions are common in critically ill patients and may
play a role in the increased risk of developing sepsis and
in the severity of the infection. Secondly, bacterial loads
can be particularly high; for example, in ventilator-asso-
ciated pneumonia, intra-abdominal abscesses or perito-
nitis. Finally, resistant bacteria can be selected by prior
antimicrobial treatment or through nosocomial trans-
mission. For the above reasons, high concentration tar-
gets may be preferable in difficult-to-treat infections
such as those caused by Pseudomonas spp., which are
associated with the highest mortality rates.
b-lactam antibiotics have long been known to have
time-dependent antibacterial activity [35]. The time
above the MIC of the infecting organism is the best para-
meter to reflect the efficacy of b-lactams [36]. In vitro
Figure 1 Pharmacokinetic profile of meropenem for patients
receiving continuous renal replacement therapy.D a t as h o w n
as mean serum concentrations (with standard deviation) measured
in samples taken < 48 hours (circles) and > 48 hours (diamonds)
from the start of the treatment. Dotted line, 2 μg/ml; dashed line,
8 μg/ml.
Figure 2 Pharmacokinetic profile of piperacillin for patients
receiving continuous renal replacement therapy.D a t as h o w n
as mean serum concentrations (with standard deviation) measured
in samples taken < 48 hours (circles) and > 48 hours (diamonds)
from the start of the treatment. Dotted line, 16 μg/ml; dashed
line, 64 μg/ml.
Figure 3 Pharmacokinetic profile of cefepime for patients
receiving continuous renal replacement therapy.D a t as h o w n
as mean serum concentrations (with standard deviation) measured
in samples taken < 48 hours (circles) and > 48 hours (diamonds)
from the start of the treatment. Dotted line, 8 μg/ml; dashed line,
32 μg/ml.
Figure 4 Pharmacokinetic profile of ceftazidime for patients
receiving continuous renal replacement therapy.D a t as h o w n
as mean serum concentrations (with standard deviation) measured
in samples taken < 48 hours (circles) and > 48 hours (diamonds)
from the start of the treatment. Dotted line, 8 μg/ml; dashed line,
32 μg/ml.
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activity was rapidly saturated at concentrations corre-
sponding to four times the MIC, so that greatly increas-
ing antibiotic concentrations (that is, above eight or 16
times the MIC) did not kill bacteria more rapidly or
more extensively [29,37]. In animal models, maximal bac-
terial killing was obtained with drug concentrations of
four or five times the MIC [38]. Unfortunately, there are
no data comparing the efficacy of different therapeutic
endpoints in the clinical setting. Microbiological success,
but not clinical cure, was significantly correlated with the
proportion of the dosing interval when FEP concentra-
tions exceeded four times the MIC in human infections
[39]. Based on these limited data, we selected specific
pharmacodynamic endpoints to assess the adequacy of b-
lactam concentrations in our study. The time during
which the serum concentration should remain above a
threshold concentration (40 to 100%) and the optimal
threshold concentrations (one to four times the MIC),
however, are still controversial [40]. In the present study,
we deliberately chose to consider the clinical breakpoint
of P. aeruginosa, commonly isolated in ICU patients with
higher MICs than most other Enterobacteriaceae and
associated with the highest mortality rates [41].
Continuous renal replacement therapy and antibiotic
concentrations
Studies on serum concentrations of broad-spectrum
b-lactams in patients undergoing haemofiltration/hae-
modiafiltration have shown varying results, but included
small and variable patient populations, CRRT types, and
MIC target values. Studies of patients on CRRT receiv-
ing MEM have proposed doses ranging from 500 mg
every 12 hours [42,43] to 1 g every 12 hours [20,44]. In
nine septic patients, the Vd was 29.5 ± 2.7 l (Vd =3 9 . 7l
(14.8 to 184.7 l) in the present study), the AUC was
118.0 ± 15.8 mg/hour/l, the total CL was 143.7 ±
18.6 ml/minute (total CL = 88.7 ml/minute (43.2 to
Table 3 Probability of time the concentration is four times MIC attainment for Pseudomonas spp
Antibiotic, daily dose (number of patients) Time period (number of series) PK/PD target attainment (number of series (%))
MEM 1 g
twice daily (n = 17)
All (n = 22) 18 (81%)
Day < 48 hours (n = 7) 5 (71%)
Days > 48 hours (n = 15) 13 (87%)
TZP 4 g
four times daily (n = 16)
All (n = 21) 15 (71%)
Day < 48 hours (n = 12) 8 (66%)
Days > 48 hours (n = 9) 7 (78%)
FEP 2 g
twice daily (n =8 )
All (n = 11) 0 (0%)
Day < 48 hours (n = 7) 0 (0%)
Days > 48 hours (n = 4) 0 (0%)
CAZ 2 g
twice daily (n = 12)
All (n = 15) 8 (53%)
Day < 48 hours (n = 8) 3 (38%)
Days > 48 hours (n = 7) 5 (71%)
Probability of target time that the concentration is four times the minimum inhibitory concentration (MIC) attainment for Pseudomonas spp. in the early (< 48
hours) and late (48 hours) phases of sepsis: meropenem (MEM), ≥ 40% of time above 8 μg/ml; piperacillin-tazobactam (TZP), ≥ 50% of time above 64 μg/ml;
cefepime (FEP) and ceftazidime (CAZ), ≥ 70% of time above 32 μg/ml. PK/PD, pharmacokinetic/pharmacodynamic.
Table 4 Probability of target time the concentration is four times the MIC attainment for various MICs
MIC (μg/ml) Target concentrations (μg/ml) MEM
(n = 22)
FEP
(n = 11)
CAZ
(n = 15)
TZP
(n = 21)
32 128 0 0 0 3 (14)
16 64 0 0 0 15 (71)
83 2 0 0 8 (53) 19 (90)
41 6 9 (41) 7 (63) 13 (87) 21 (100)
28 18 (81) 10 (90) 15 (100) 21 (100)
1 4 22 (100) 11 (100) 15 (100) 21 (100)
0.5 2 22 (100) 11 (100) 15 (100) 21 (100)
Data expressed as numbers of series (percentages). Data in bold show targets attained in at least 90% of patients for the indicated minimum inhibitory
concentrations (MICs) corresponding to European Committee on Antimicrobial Susceptibility Testing clinical breakpoints for Pseudomonas aeruginosa.M E M ,
meropenem; FEP, cefepime; CAZ, ceftazidime; TZP, piperacillin-tazobactam.
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2.33 ± 0.38 hours [42]. On the basis of a literature
review, Trotman and colleagues suggested doses of 1 g
every 12 hours for CVVH or CVVHDF [16]. In our
study, we found using these recommended doses that
adequate concentrations of MEM were obtained only
for pathogens with an MIC up to 1 μg/ml.
For TZP, doses of 4.0/0.5 g every 12 hours were
reported to be insufficient for Enterobacteriaceae and
Pseudomonas spp. in six patients on CVVH or CVVHDF
[45]; these authors suggested adding an extra dose daily.
The adequacy of 4.0/0.5 g three times daily was reported
in a study of nine patients on CRRT who maintained con-
centrations > 125 μg/ml for the whole time interval [46].
Simulations to reach a MIC of 32 μg/ml have also been
obtained with 4.0/0.5 g every 12 hours or 2.0/0.25 g every
8 hours [19]. In this latter study, a mean Vd of 0.31 ±
0.07 l/kg, a median piperacillin total CL of 47 ml/minute
(26 to 220 ml/minute) and a mean t1/2 of 4.3 ± 1.2 hours
were found [19]. These results were comparable with
those found in our study. Even with a slightly higher dose
of TZP (4.0/0.5 g every 6 hours in our study) than that
proposed by Trotman (3.0/0.375 g every 6 hours), how-
ever, our patients did not reach adequate concentrations
for higher MICs.
Malone and colleagues confirmed that FEP was elimi-
nated well by CRRT but that 2 g daily would be sufficient
for MICs < 8 μg/ml [17]; higher MICs may need 4 g/day.
In this study, the authors reported a Vd of 0.46 ± 0.14 l/kg,
a CL of 0.40 ± 0.09 ml/minute/kg, and a t1/2 of 12.9 ± 2.6
hours [17], similar to our study. Similarly, results in one
study of six patients on CVVHDF receiving 2 g twice daily
were judged satisfactory given the trough concentrations
of 17.7 μg/ml [47]. Despite using these doses in our study,
FEP showed the worst results, except for very susceptible
organisms. Studies on CAZ have also given discordant
results: Matzke and colleagues proposed 250-750 mg/day
depending on the residual renal function [18]. Other
authors opted for maintaining the usual doses of 2 g three
times daily for susceptible bacteria, and even suggested 3 g
three times daily for higher MICs [48]; these authors
reported maximum and trough concentrations compar-
able with those found in our study, with mean pharmaco-
kinetic parameters as follows: peak concentration = 58.2 ±
11.6 mg/l, AUC = 344 ± 51.6 mg/hour/l, total CL = 98.7 ±
13.2 ml/minute and t1/2 =4 . 3±0 . 6h o u r s .
According to all these data, optimisation of b-lactam
regimens should be considered in cases of infection by less
susceptible pathogens in septic patients during CRRT.
Over the past couple of years, studies have emerged on
prolonged [49] or continuous infusions of b-lactam anti-
biotics [11,21,49-51] to increase their antibacterial activity.
Nevertheless, data on the efficacy of prolonged or
continuous drug infusions during CRRT are scarce [52,53]
and further studies are necessary to evaluate this strategy
in this setting. Importantly, when drug monitoring is per-
formed in ICU patients, b-lactam regimens were modified
in most patients, either because of insufficient concentra-
tions or antibiotic accumulation [54]. Therapeutic drug
monitoring should therefore be performed in this setting
whenever possible.
Advantages and limitations
Unlike other studies using well-controlled steady-state
conditions, our study was conducted in a real-life setting
in acutely ill patients in the ICU. We studied consecutive
patients without exclusion. All patients had severe sepsis
(with or without septic shock) and were included in the
early stage of sepsis. Due to their unstable condition,
CRRT parameters were modified many times in the course
of each antibiotic treatment. This contrasts with studies
performed in selected stable patients with unchanged
CRRT parameters, and makes our study a close reflection
of everyday practice, rendering our results more relevant
and applicable to severely ill patients in mixed ICUs.
The present study has some limitations. First, as only
free drug is the active moiety, it has been recommended
that all pharmacokinetic/pharmacodynamic indices should
be referenced to the unbound (free) fraction of the drug,
especially for some drugs such as piperacillin that has 20
to 30% protein binding. Nevertheless, in the case of FEP,
differences in total and free concentrations are between 2
and 6%. We considered that the protein binding was negli-
gible for all four antibiotics and used the total concentra-
tion of each antibiotic in the analyses; however, we cannot
present any data on free drug levels. Second, CRRT use
was not standardised and contributed to the large variabil-
ity of pharmacokinetic parameters observed over the study
period. Third, we did not simulate any dose regimens that
would have resulted in adequate drug concentrations in
our cohort of patients, and a prospective study with dose
adaption during CRRT is needed in this setting. Moreover,
it is possible that critically ill patients undergoing CRRT
would also need a larger than recommended loading dose
for b-lactams, as recently shown for a large septic popula-
tion [14]; however, no loading dose analysis was included
in our study. Finally, we did not collect microbiological
data or daily severity scores, such as daily Sequential
Organ Failure Assessment, and we cannot provide any
data on the relationship between drug concentrations and
clinical efficacy or evolution of organ dysfunction.
Conclusions
At the onset of sepsis in patients receiving CRRT, we
suggest that similar b-lactam doses to those used in the
absence of renal failure should be given during the first
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four times daily, and FEP and CAZ at doses of 2 g three
times daily. Dose reduction should be considered there-
after to avoid drug accumulation. Considering the large
pharmacokinetics variability, therapeutic drug monitor-
ing of b-lactams should be performed to optimise anti-
biotic efficacy.
Key messages
￿ In the first 48 hours of treatment for patients with
sepsis receiving CRRT, antibiotic concentrations
were inadequate to maintain therapeutic serum con-
centrations greater than four times the MIC of P.
aeruginosa in 29%, 34%, 62% and 100% of patients
receiving MEM, TZP, CAZ and FEP, respectively, if
given at the current recommended doses for CRRT.
￿ For patients on CRRT, we recommend using the
same antibiotic doses for MEM, TZP, FEP and CAZ as
those used in patients without renal failure for the first
48 hours of treatment.
￿ There may be some accumulation of antibiotic
after the first 48 hours of treatment in patients on
CRRT, justifying use of drug monitoring whenever
possible.
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